Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
LeMaitre Vascular director Joseph P. Pellegrino Jr. exercised stock options to acquire 2,941 shares of Common Stock at $35.48 per share. These shares came from a fully vested option that was exercised in full, leaving no remaining derivative position from this grant. Following the transaction, he directly owns 15,021 Common shares, making this a routine compensation-related option exercise rather than an open-market purchase or sale.
LeMaitre Vascular, Inc. is asking stockholders to vote at its 2026 annual meeting on June 2, 2026, in Burlington, Massachusetts. Investors will elect two Class II directors, cast an advisory say-on-pay vote on 2025 executive compensation, and ratify Grant Thornton LLP as auditor for 2026.
The proxy highlights a seven‑member, largely independent board with extensive medical device and financial expertise, and describes governance practices such as a director resignation policy, clawback policy, insider trading restrictions, and board‑level risk oversight. It also discloses major shareholders and 2025 executive pay structure, which ties a significant portion of compensation to financial and operational performance.
LeMaitre Vascular, Inc. reports upcoming changes to its Board of Directors tied to the 2026 Annual Meeting of Stockholders on June 2, 2026. Bridget Ross, a Class II director, has informed the Board she will not stand for re-election and will serve until her current term ends at that meeting. The company states her decision is not due to any disagreement regarding operations, policies, or practices.
To rebalance the staggered board, the Board has nominated David B. Roberts to stand for election as a Class II director at the same meeting. In connection with this nomination, Mr. Roberts has indicated he will resign as a Class I director at the conclusion of the meeting, contingent on his election as a Class II director. After these changes, the Board will have seven members instead of eight, structured as two Class I directors, two Class II directors, and three Class III directors, consistent with the company’s charter and by-law provisions allowing the Board to set its own size.
LeMaitre Vascular director Martha Shadan reported equity-based compensation awards, not open-market trades. On March 26, 2026, she was granted several small blocks of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025.
Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying stock awards. All transactions are coded as awards or other acquisitions, with no reported share purchases or sales in the market.
LEMAITRE VASCULAR INC director Bridget A. Ross reported compensation-related awards of dividend equivalent rights tied to existing equity grants. On March 26, 2026, she acquired several small blocks of dividend equivalent rights, each economically equivalent to one share of common stock and linked to prior restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. These rights vest proportionately with the underlying awards and reflect routine equity compensation accruals rather than open-market trading.
LeMaitre Vascular director John James O'Connor reported grants of dividend equivalent rights linked to existing stock awards. On March 26, 2026, he acquired several small blocks of Dividend Equivalent Rights, each economically equivalent to one share of LeMaitre common stock.
The rights accrued on previously granted restricted stock unit and performance share unit awards from December 8, 2023, December 6, 2024, and December 10, 2025, and will vest proportionately with those underlying awards. These are compensation-related accruals rather than open‑market share purchases or sales.
LeMaitre Vascular director John A. Roush reported grants of dividend equivalent rights tied to prior equity awards. On March 26, 2026, he acquired several small fractional awards of Dividend Equivalent Rights, each economically equal to one share of LeMaitre Vascular common stock.
The rights accrued on restricted stock unit and performance share unit awards originally granted on December 8, 2023, December 6, 2024, and December 10, 2025, and they vest proportionately with those underlying awards. These are compensation-related accruals rather than open-market stock purchases or sales.
LEMAITRE VASCULAR INC director Lawrence J. Jasinski reported routine compensation-related grants of dividend equivalent rights. On March 26, 2026, he acquired several small fractional awards of dividend equivalent rights linked to existing restricted stock unit and performance share unit grants from December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying stock or performance awards. These are non-cash, derivative awards and do not represent any open-market share purchases or sales.
LeMaitre Vascular director Joseph P. Pellegrino Jr. reported multiple awards of dividend equivalent rights on derivative securities. On March 26, 2026, he acquired several small grants of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards.
Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying equity awards granted in 2022, 2023, and 2024–2025. These are compensation-related accruals, with no open-market purchases or sales reported in this filing.